A satellite symposium in conjunction with Oncology Pharmacists Connect 2023.
If you would like to attend in person, please visit our Oncology Pharmacists Connect 2023 registration page: www.pharmacytimes.org/Connect2023
Program Description
Non-melanoma skin cancers, which include basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and Merkel cell carcinoma (MCC), are skin malignancies with diverse clinical presentations and unique pathophysiological characteristics. Response rates to cytotoxic chemotherapy regimens have generally been low, and the toxicity profiles of these regimens limit their use. Recent advances in the use of immune checkpoint inhibitors (ICIs) for treatment of non-melanoma skin cancers have contributed to substantial improvements in patient response and survival outcomes, especially in advanced or metastatic disease. Pharmacists on the multidisciplinary oncology care team must be well versed in the management of immune-related adverse effects associated with ICI therapies, as these adverse effects can be associated with premature discontinuation of therapy. This program will examine the expanding role of ICIs in the treatment of non-melanoma skin cancers as well as optimal strategies for prevention of disease and mitigation of immune-related adverse effects.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: June 16, 2023
Expiration date: August 16, 2023
Time to complete activity: 1.0 hour
Learner level: Intermediate, Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the use of immune checkpoint inhibitors in the treatment of advanced or metastatic basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)
- Personalize treatment selection for patients with advanced/metastatic BCC or SCC considering patient- and disease-specific factors
- Employ the latest guidelines and clinical recommendations for the management of dermatologic immune-related adverse effects and their implications on the treatment plan
Heather Armbruster, PharmD, BCOP
Pharmacy Manager, Outpatient Clinical Services
The James Cancer Hospital at The Ohio State University
Columbus, Ohio
Jordan McPherson, PharmD, BCOP
Oncology Clinical Pharmacist, Huntsman Cancer Institute
Adjunct Assistant Professor, College of Pharmacy, University of Utah
Salt Lake City, Utah
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-23-220-L01-P. The activity is available for CE credit through August 16, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Jordan McPherson, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Hitachi, Ltd. (Research Support)- Content unrelated to presentation
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Heather Armbruster, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms